Evidence map›Paper›PMID 34393798›Full record

ArticleFrontiers in pharmacology2021

The Potential of Lisosan G as a Possible Treatment for Glaucoma.

Rosario Amato, Maria Grazia Rossino, Maurizio Cammalleri, Anna Maria Timperio, Giuseppina Fanelli, Massimo Dal Monte, Laura Pucci, Giovanni Casini

Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05855577 (-Clinical Efficacy of Pharmacological Treatments Targeting Energy Metabolism, Evaluated by Gait Analysis, on Motor Function in Parkinson's Disease Patients), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05855577 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

-Clinical Efficacy of Pharmacological Treatments Targeting Energy Metabolism, Evaluated by Gait Analysis, on Motor Function in Parkinson's Disease Patients

TypeinterventionalSponsorI.R.C.C.S. Fondazione Santa LuciaRan2023 to 2026Enrolled50ConditionsParkinson Disease, Gait Analysis, Therapy, Directly Observed, Metabolic DiseaseArmsTerazosin
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rosario AmatoDepartment of Biology, University of Pisa, Pisa, Italy.
Maria Grazia RossinoDepartment of Biology, University of Pisa, Pisa, Italy.
Maurizio CammalleriDepartment of Biology, University of Pisa, Pisa, Italy.
Anna Maria TimperioDepartment of Ecological and Biological Sciences, University of Tuscia, Viterbo, Italy.
Giuseppina FanelliDepartment of Agriculture and Forest Sciences, University of Tuscia, Viterbo, Italy.
Massimo Dal MonteDepartment of Biology, University of Pisa, Pisa, Italy.
Laura PucciNational Research Council, Institute of Agricultural Biology and Biotechnology (IBBA), Pisa, Italy.
Giovanni CasiniDepartment of Biology, University of Pisa, Pisa, Italy.
University of Pisa · ITUniversità degli Studi della Tuscia · ITNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lisosan G (LG), a fermented powder obtained from whole grains, is a nutritional supplement containing a variety of metabolites with documented antioxidant properties. We have recently demonstrated that orally administered LG protects diabetic rodent retinas from oxidative stress, inflammation, apoptosis, blood-retinal barrier disruption, and functional damage. Here, we investigated whether LG may exert protective effects in a model of glaucoma and measured the amounts of selected LG components that reach the retina after oral LG administration. Six-month-old DBA/2J mice were given an aqueous LG solution in place of drinking water for 2 mo. During the 2 mo of treatment with LG, the intraocular pressure (IOP) was monitored and the retinal ganglion cell (RGC) functional activity was recorded with pattern-electroretinography (PERG). At the end of the 2-mo period, the expression of oxidative stress and inflammatory markers was measured with qPCR, and RGC survival or macroglial activation were assessed with immunofluorescence. Alternatively, LG was administered by gavage and the concentrations of four of the main LG components (nicotinamide, gallic acid, 4-hydroxybenzoic acid, and quercetin) were measured in the retinas in the following 24 h using mass spectrometry. LG treatment in DBA/2J mice did not influence IOP, but it affected RGC function since PERG amplitude was increased and PERG latency was decreased with respect to untreated DBA/2J mice. This improvement of RGC function was concomitant with a significant decrease of both oxidative stress and inflammation marker expression, of RGC loss, and of macroglial activation. All four LG metabolites were found in the retina, although with different proportions with respect to the amount in the dose of administered LG, and with different temporal profiles in the 24 h following administration. These findings are consistent with neuroenhancing and neuroprotective effects of LG in glaucoma that are likely to derive from its powerful antioxidant properties. The co-occurrence of different metabolites in LG may provide an added value to their beneficial effects and indicate LG as a basis for the potential treatment of a variety of retinal pathologies.

Indexed as

inflammationneuroprotectionnutraceuticalsoxidative stresspattern electroretinogram

Identifiers

PMID34393798
PMCPMC8355587
OpenAlexW3183927234

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.